GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Long-Term Debt

Implantica AG (OSTO:IMP A SDB) Long-Term Debt : kr0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Long-Term Debt?

Implantica AG's Long-Term Debt for the quarter that ended in . 20 was kr0.00 Mil.


Implantica AG Long-Term Debt Historical Data

The historical data trend for Implantica AG's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Long-Term Debt Chart

Implantica AG Annual Data
Trend
Long-Term Debt

Implantica AG Semi-Annual Data
Long-Term Debt

Implantica AG  (OSTO:IMP A SDB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Implantica AG Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Implantica AG's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines